Raymond James analyst Steven Seedhouse initiated coverage of Wave Life Sciences with an Outperform rating and $7 price target. Wave is the leader to clinic in RNA editing with WVE-006 for alpha-1 antitrypsin deficiency, which is expected to begin first in human studies early next year, the analyst tells investors in a research note. The firm says AATD is an optimal proof-of-concept indication given both loss of function and gain of function.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WVE:
- Wave Life Sciences joins Russell 2000, Russell 3000 Indexes
- Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
- Wave Life Sciences Notches Higher despite Drug Trial Setback
- Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
- Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting